Shiffman, M. L., Muir, A. J., Vierling, J. M., Gordon, S. C., Kugelmas, M., Wu, G. Y., … Apelian, D. (2012). GI-5005 Therapeutic Vaccine Enhances Virologic Clearance By Peg-IFN/Ribavirin In Naive HCV Genotype 1 Patients With IL28B Genotype T/T. In HEPATOLOGY (Vol. 56, pp. 570A-571A). Boston, MA: WILEY-BLACKWELL.

Shiffman, Mitchell L., Andrew J. Muir, John M. Vierling, Stuart C. Gordon, Marcelo Kugelmas, George Y. Wu, Tuan T. Nguyen, et al. “GI-5005 Therapeutic Vaccine Enhances Virologic Clearance By Peg-IFN/Ribavirin In Naive HCV Genotype 1 Patients With IL28B Genotype T/T.” In HEPATOLOGY, 56:570A-571A. WILEY-BLACKWELL, 2012.

Shiffman ML, Muir AJ, Vierling JM, Gordon SC, Kugelmas M, Wu GY, et al. GI-5005 Therapeutic Vaccine Enhances Virologic Clearance By Peg-IFN/Ribavirin In Naive HCV Genotype 1 Patients With IL28B Genotype T/T. In: HEPATOLOGY. WILEY-BLACKWELL; 2012. p. 570A-571A.

Shiffman, Mitchell L., et al. “GI-5005 Therapeutic Vaccine Enhances Virologic Clearance By Peg-IFN/Ribavirin In Naive HCV Genotype 1 Patients With IL28B Genotype T/T.” HEPATOLOGY, vol. 56, WILEY-BLACKWELL, 2012, pp. 570A-571A.

Shiffman ML, Muir AJ, Vierling JM, Gordon SC, Kugelmas M, Wu GY, Nguyen TT, Balart LA, McHutchison JG, Armstrong BR, Mann DL, Guo Z, King TH, Ferraro J, Mattson A, Rodell TC, Apelian D. GI-5005 Therapeutic Vaccine Enhances Virologic Clearance By Peg-IFN/Ribavirin In Naive HCV Genotype 1 Patients With IL28B Genotype T/T. HEPATOLOGY. WILEY-BLACKWELL; 2012. p. 570A-571A.